Molecular cell biology and immunobiology of mammalian rod/ring structures

International Review of Cell and Molecular Biology

Volumn 308, Issue , 2014, Pages 35-74

  Carcamo, Wendy C ^a   Calise, S John ^a   von Mühlen, Carlos A ^b   Satoh, Minoru ^c,d   Chan, Edward K L ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b Rheuma Clinic for Rheumatic Diseases   (Brazil)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Cytidine triphosphate synthetase; Embryonic stem cells; Hepatitis C; Inosine monophosphate dehydrogenase; Mycophenolic acid; Nucleotide metabolism; Ribavirin

Indexed keywords

AUTOANTIBODY; CYTIDINE TRIPHOSPHATE; CYTIDINE TRIPHOSPHATE SYNTHASE; DIHYDROFOLATE REDUCTASE; GUANOSINE TRIPHOSPHATE; INOSINATE DEHYDROGENASE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEMATIN; PEGINTERFERON ALPHA; PEMETREXED; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; RIBAVIRIN; SACCHAROMYCES CEREVISIAE PROTEIN; THYMIDINE TRIPHOSPHATE; THYMIDYLATE SYNTHASE; TUBULIN; UNCLASSIFIED DRUG; VIMENTIN; LIGASE;

ARTICLE; AUTOIMMUNITY; BACTERIUM; CAULOBACTER CRESCENTUS; CELL GROWTH; CELL NUCLEUS; CELL ORGANELLE; CELLULAR, SUBCELLULAR AND MOLECULAR BIOLOGICAL PHENOMENA AND FUNCTIONS; CYTOPLASM; DROSOPHILA; GENETIC CONSERVATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOBIOLOGY; LOUKOUMASOME; MAMMAL CELL; METABOLISM; NONHUMAN; NUCLEOTIDE METABOLISM; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN POLYMERIZATION; PURINE METABOLISM; RHEUMATIC DISEASE; SACCHAROMYCES CEREVISIAE; SCLERODERMA; SJOEGREN SYNDROME; SYMPATHETIC NERVE CELL; SYSTEMIC LUPUS ERYTHEMATOSUS; VIRUS MORPHOLOGY; YEAST; ANIMAL; CYTOLOGY; IMMUNOLOGY; MOLECULAR BIOLOGY; ULTRASTRUCTURE;

ALLERGY AND IMMUNOLOGY; ANIMALS; CARBON-NITROGEN LIGASES; CELL BIOLOGY; CYTOPLASMIC STRUCTURES; HUMANS; IMP DEHYDROGENASE; MOLECULAR BIOLOGY;

EID: 84892150916     PISSN: 19376448     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-800097-7.00002-6     Document Type: Chapter

References (125)

1. Alderuccio F., Chan E.K.L., Tan E.M. Molecular characterization of an autoantigen of PM-Scl in the polymyositis/scleroderma overlap syndrome: a unique and complete human cDNA encoding an apparent 75-kD acidic protein of the nucleolar complex. J. Exp. Med. 1991, 173:941-952.
2. Allison A.C., Eugui E.M. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol. Rev. 1993, 136:5-28.
3. Alter H.J., Seeff L.B. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin. Liver Dis. 2000, 20:17-35.
4. An S., Kumar R., Sheets E.D., Benkovic S.J. Reversible compartmentalization of de novo purine biosynthetic complexes in living cells. Science 2008, 320:103-106.
5. Andrade L.E.C., Chan E.K.L., Raska I., Peebles C.L., Roos G., Tan E.M. Human autoantibody to a novel protein of the nuclear coiled body: immunological characterization and cDNA cloning of p80-coilin. J. Exp. Med. 1991, 173:1407-1419.
6. Azzam G., Liu J.L. Only one isoform of Drosophila melanogaster CTP synthase forms the cytoophidium. PLoS Genet. 2013, 9:e1003256.
7. Baechler E.C., Batliwalla F.M., Karypis G., Gaffney P.M., Ortmann W.A., Espe K.J., et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:2610-2615.
8. Bartenschlager R., Lohmann V. Replication of hepatitis C virus. J. Gen. Virol. 2000, 81:1631-1648.
9. Bartosch B., Cosset F.L. Cell entry of hepatitis C virus. Virology 2006, 348:1-12.
10. Bateman A. The structure of a domain common to archaebacteria and the homocystinuria disease protein. Trends Biochem. Sci. 1997, 22:12-13.
11. Beaty N.B., Lane M.D. Kinetics of activation of acetyl-CoA carboxylase by citrate. Relationship to the rate of polymerization of the enzyme. J. Biol. Chem. 1983, 258:13043-13050.
12. Bennett L., Palucka A.K., Arce E., Cantrell V., Borvak J., Banchereau J., et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 2003, 197:711-723.
13. Bortolotti F., Vajro P., Balli F., Giacchino R., Crivellaro C., Barbera C., et al. Non-organ specific autoantibodies in children with chronic hepatitis C. J. Hepatol. 1996, 25:614-620.
14. Bowne S.J., Sullivan L.S., Blanton S.H., Cepko C.L., Blackshaw S., Birch D.G., et al. Mutations in the inosine monophosphate dehydrogenase 1 gene (IMPDH1) cause the RP10 form of autosomal dominant retinitis pigmentosa. Hum. Mol. Genet. 2002, 11:559-568.
15. Bowne S.J., Sullivan L.S., Mortimer S.E., Hedstrom L., Zhu J., Spellicy C.J., et al. Spectrum and frequency of mutations in IMPDH1 associated with autosomal dominant retinitis pigmentosa and leber congenital amaurosis. Invest. Ophthalmol. Vis. Sci. 2006, 47:34-42.
16. Boyer J.L., Chang E.B., Collyar D.E., DeLeve L.D., Feinberg J., Judge T.A., et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C 2002 (June 10-12, 2002). Gastroenterology 2002, 123:2082-2099.
17. Calise S.J., Carcamo W.C., Ceribelli A., Dominguez Y., Satoh M., Chan E.K.L. Antibodies to rods and rings. Autoantibodies 2014, Elsevier Science, San Diego, CA. Y. Shoenfeld, M.E. Gershwin, P.L. Meroni (Eds.).
18. Carcamo W.C., Yao B., Satoh M., Reeves W.H., Liu C., Covini G., et al. Cytoplasmic rings/rods as autoimmune targets of emerging human autoantibodies associated with HCV virus infection and interferon therapy. From Pathogenesis to Therapy of Autoimmune Diseases 2009, 127-134. Pabst Science Publishers, Lengerich, Germany. K. Conrad, E.K.L. Chan, M.J. Fritzler, R.L. Humbel, P. von Landenberg, Y. Shoenfeld (Eds.).
19. Carcamo W.C., Satoh M., Kasahara H., Terada N., Hamazaki T., Chan J.Y., et al. Induction of cytoplasmic rods and rings structures by inhibition of the CTP and GTP synthetic pathway in mammalian cells. PLoS One 2011, 6:e29690.
20. Carcamo W.C., Calise S.J., Krueger C.E., Purich D.L., Chan E.K.L. Glutamine deprivation initiates reversible assembly of cytoplasmic rods and rings. Cell. Mol. Life Sci. 2014, in revision.
21. Carcamo W.C., Ceribelli A., Calise S.J., Krueger C., Liu C., Daves M., et al. Differential reactivity to IMPDH2 by anti-rods/rings autoantibodies and unresponsiveness to pegylated interferon-alpha/ribavirin therapy in US and Italian HCV patients. J. Clin. Immunol. 2013, 33:420-426.
22. Chan E.K.L., Andrade L.E.C. Antinuclear antibodies in Sjogren's syndrome. Rheum. Dis. Clin. North Am. 1992, 18:551-570.
23. Chan E.K.L., Fritzler M.J. Autoantibodies to Golgi Apparatus antigens. Pathogenic and Diagnostic Relevance of Autoantibodies 1998, 85-100. Pabst Science Publishers, Scottsdale, AZ. K. Conrad, R.L. Humbel, M. Meurer, Y. Shoenfeld, E.M. Tan (Eds.).
24. Chan E.K.L., Fritzler M.J. Introduction: the GW body story as an example of autoantibodies with significant impacts to molecular cell biology. Adv. Exp. Med. Biol. 2013, 768:1-4.
25. Chan E.K.L., Imai H., Hamel J.C., Tan E.M. Human autoantibody to RNA polymerase I transcription factor hUBF. Molecular identity of nucleolus organizer region autoantigen NOR-90 and ribosomal RNA transcription upstream binding factor. J. Exp. Med. 1991, 174:1239-1244.
26. Chan E.K.L., Takano S., Andrade L.E., Hamel J.C., Matera A.G. Structure, expression and chromosomal localization of human p80-coilin gene. Nucleic Acids Res. 1994, 22:4462-4469.
27. Charlton M. Hepatitis C infection in liver transplantation. Am. J. Transplant. 2001, 1:197-203.
28. Chen K., Zhang J., Tastan O.Y., Deussen Z.A., Siswick M.Y., Liu J.L. Glutamine analogs promote cytoophidium assembly in human and Drosophila cells. J. Genet. Genomics 2011, 38:391-402.
29. Choo Q.L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989, 244:359-362.
30. Cocquerel L., Voisset C., Dubuisson J. Hepatitis C virus entry: potential receptors and their biological functions. J. Gen. Virol. 2006, 87:1075-1084.
31. Colby T.D., Vanderveen K., Strickler M.D., Markham G.D., Goldstein B.M. Crystal structure of human type II inosine monophosphate dehydrogenase: implications for ligand binding and drug design. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:3531-3536.
32. Covini G., Chan E.K.L., Nishioka M., Morshed S.A., Reed S.I., Tan E.M. Immune response to cyclin B1 in hepatocellular carcinoma. Hepatology 1997, 25:75-80.
33. Covini G., Carcamo W.C., Bredi E., von Muhlen C.A., Colombo M., Chan E.K.L. Cytoplasmic rods and rings autoantibodies developed during pegylated interferon and ribavirin therapy in patients with chronic hepatitis C. Antivir. Ther. 2012, 17:805-811.
34. Cresta P., Musset L., Cacoub P., Frangeul L., Vitour D., Poynard T., et al. Response to interferon alpha treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus. Gut 1999, 45:122-128.
35. Dammacco F., Sansonno D., Piccoli C., Racanelli V., D'Amore F.P., Lauletta G. The lymphoid system in hepatitis C virus infection: autoimmunity, mixed cryoglobulinemia, and Overt B-cell malignancy. Semin. Liver Dis. 2000, 20:143-157.
36. Dereuddre-Bosquet N., Roy B., Routledge K., Clayette P., Foucault G., Lepoivre M. Inhibitors of CTP biosynthesis potentiate the anti-human immunodeficiency virus type 1 activity of 3TC in activated peripheral blood mononuclear cells. Antiviral Res. 2004, 61:67-70.
37. Drygiannakis D., Lionis C., Drygiannakis I., Pappas G., Kouroumalis E. Low prevalence of liver-kidney microsomal autoantibodies of type 1 (LKM1) in hepatitis C seropositive subjects on Crete, Greece. BMC Gastroenterol. 2001, 1:4.
38. Dustin L.B., Rice C.M. Flying under the radar: the immunobiology of hepatitis C. Annu. Rev. Immunol. 2007, 25:71-99.
39. Evans M.J., von Hahn T., Tscherne D.M., Syder A.J., Panis M., Wolk B., et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007, 446:801-805.
40. Eystathioy T., Jakymiw A., Fujita D.J., Fritzler M.J., Chan E.K.L. Human autoantibodies to a novel Golgi protein golgin-67: high similarity with golgin-95/gm 130 autoantigen. J. Autoimmun. 2000, 14:179-187.
41. Eystathioy T., Chan E.K.L., Tenenbaum S.A., Keene J.D., Griffith K., Fritzler M.J. A phosphorylated cytoplasmic autoantigen, GW182, associates with a unique population of human mRNAs within novel cytoplasmic speckles. Mol. Biol. Cell 2002, 13:1338-1351.
42. Ferri C., Zignego A.L. Relation between infection and autoimmunity in mixed cryoglobulinemia. Curr. Opin. Rheumatol. 2000, 12:53-60.
43. Foy E., Li K., Wang C., Sumpter R., Ikeda M., Lemon S.M., et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003, 300:1145-1148.
44. Franklin T.J., Cook J.M. The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem. J. 1969, 113:515-524.
45. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales F.L., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002, 347:975-982.
46. Fritzler M.J. Autoantibodies in scleroderma. J. Dermatol. 1993, 20:257-268.
47. Fritzler M.J., Chan E.K.L. The discovery of GW bodies. Adv. Exp. Med. Biol. 2013, 768:5-21.
48. Furuta K., Chan E.K.L., Kiyosawa K., Reimer G., Luderschmidt C., Tan E.M. Heterochromatin protein HP1Hsbeta (p25beta) and its localization with centromeres in mitosis. Chromosoma 1997, 106:11-19.
49. Gunter J.H., Thomas E.C., Lengefeld N., Kruger S.J., Worton L., Gardiner E.M., et al. Characterisation of inosine monophosphate dehydrogenase expression during retinal development: differences between variants and isoforms. Int. J. Biochem. Cell Biol. 2008, 40:1716-1728.
50. Hadziyannis S.J. The spectrum of extrahepatic manifestations in hepatitis C virus infection. J. Viral Hepat. 1997, 4:9-28.
51. Hadziyannis S.J., Sette H., Morgan T.R., Balan V., Diago M., Marcellin P., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 2004, 140:346-355.
52. Hardin J.A. The lupus autoantigens and the pathogenesis of systemic lupus erythematosus. Arthritis Rheum. 1986, 29:457-460.
53. Hedstrom L. IMP dehydrogenase: structure, mechanism, and inhibition. Chem. Rev. 2009, 109:2903-2928.
54. Hofer A., Steverding D., Chabes A., Brun R., Thelander L. Trypanosoma brucei CTP synthetase: a target for the treatment of African sleeping sickness. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:6412-6416.
55. Hong Z., Cameron C.E. Pleiotropic mechanisms of ribavirin antiviral activities. Prog. Drug Res. 2002, 59:41-69.
56. Hoofnagle J.H. Course and outcome of hepatitis C. Hepatology 2002, 36:S21-S29.
57. Ignoul S., Eggermont J. CBS domains: structure, function, and pathology in human proteins. Am. J. Physiol. Cell Physiol. 2005, 289:C1369-C1378.
58. Ingerson-Mahar M., Briegel A., Werner J.N., Jensen G.J., Gitai Z. The metabolic enzyme CTP synthase forms cytoskeletal filaments. Nat. Cell Biol. 2010, 12:739-746.
59. Jackson R.C., Weber G., Morris H.P. IMP dehydrogenase, an enzyme linked with proliferation and malignancy. Nature 1975, 256:331-333.
60. Jakymiw A., Ikeda K., Fritzler M.J., Reeves W.H., Satoh M., Chan E.K.L. Autoimmune targeting of key components of RNA interference. Arthritis Res. Ther. 2006, 8:R87.
61. Jakymiw A., Pauley K.M., Li S., Ikeda K., Lian S., Eystathioy T., et al. The role of GW/P-bodies in RNA processing and silencing. J. Cell Sci. 2007, 120:1317-1323.
62. Ji Y., Gu J., Makhov A.M., Griffith J.D., Mitchell B.S. Regulation of the interaction of inosine monophosphate dehydrogenase with mycophenolic acid by GTP. J. Biol. Chem. 2006, 281:206-212.
63. Kammer A.R., van der Burg S.H., Grabscheid B., Hunziker I.P., Kwappenberg K.M., Reichen J., et al. Molecular mimicry of human cytochrome P450 by hepatitis C virus at the level of cytotoxic T cell recognition. J. Exp. Med. 1999, 190:169-176.
64. Kato N. Genome of human hepatitis C virus (HCV): gene organization, sequence diversity, and variation. Microb. Comp. Genomics 2000, 5:129-151.
65. Kau A., Vermehren J., Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J. Hepatol. 2008, 49:634-651.
66. Kemp B.E. Bateman domains and adenosine derivatives form a binding contract. J. Clin. Invest. 2004, 113:182-184.
67. Kennan A., Aherne A., Palfi A., Humphries M., McKee A., Stitt A., et al. Identification of an IMPDH1 mutation in autosomal dominant retinitis pigmentosa (RP10) revealed following comparative microarray analysis of transcripts derived from retinas of wild-type and Rho(-/-) mice. Hum. Mol. Genet. 2002, 11:547-557.
68. Keppeke G.D., Nunes E., Ferraz M.L., Silva E.A., Granato C., Chan E.K.L., et al. Longitudinal Study of a Human Drug-Induced Model of Autoantibody to Cytoplasmic Rods/Rings following HCV Therapy with Ribavirin and Interferon-alpha. PLoS One 2012, 7:e45392.
69. Kleinschmidt A.K., Moss J., Lane D.M. Acetyl coenzyme A carboxylase: filamentous nature of the animal enzymes. Science 1969, 166:1276-1278.
70. Kohaar I., Ploss A., Korol E., Mu K., Schoggins J.W., O'Brien T.R., et al. Splicing diversity of the human OCLN gene and its biological significance for hepatitis C virus entry. J. Virol. 2010, 84:6987-6994.
71. Kursula P., Flodin S., Ehn M., Hammarstrom M., Schuler H., Nordlund P., et al. Structure of the synthetase domain of human CTP synthetase, a target for anticancer therapy. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 2006, 62:613-617.
72. Lauer G.M., Walker B.D. Hepatitis C virus infection. N. Engl. J. Med. 2001, 345:41-52.
73. Lenzi M., Bellentani S., Saccoccio G., Muratori P., Masutti F., Muratori L., et al. Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort. Gut 1999, 45:435-441.
74. Lindenbach B.D., Rice C.M. Unravelling hepatitis C virus replication from genome to function. Nature 2005, 436:933-938.
75. Liu J.L. Intracellular compartmentation of CTP synthase in Drosophila. J. Genet. Genomics 2010, 37:281-296.
76. Liu J.L. The enigmatic cytoophidium: compartmentation of CTP synthase via filament formation. Bioessays 2011, 33:159-164.
77. Liu J.L., Gall J.G. U bodies are cytoplasmic structures that contain uridine-rich small nuclear ribonucleoproteins and associate with P bodies. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:11655-11659.
78. Lohmann V., Koch J.O., Bartenschlager R. Processing pathways of the hepatitis C virus proteins. J. Hepatol. 1996, 24:11-19.
79. Luo J.C., Hwang S.J., Li C.P., Lu R.H., Chan C.Y., Wu J.C., et al. Clinical significance of serum auto-antibodies in Chinese patients with chronic hepatitis C: negative role of serum viral titre and genotype. J. Gastroenterol. Hepatol. 1998, 13:475-479.
80. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
81. McLean J.E., Hamaguchi N., Belenky P., Mortimer S.E., Stanton M., Hedstrom L. Inosine 5'-monophosphate dehydrogenase binds nucleic acids in vitro and in vivo. Biochem. J. 2004, 379:243-251.
82. McMurray R.W., Elbourne K. Hepatitis C virus infection and autoimmunity. Semin. Arthritis Rheum. 1997, 26:689-701.
83. Narayanaswamy R., Levy M., Tsechansky M., Stovall G.M., O'Connell J.D., Mirrielees J., et al. Widespread reorganization of metabolic enzymes into reversible assemblies upon nutrient starvation. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:10147-10152.
84. Noree C., Sato B.K., Broyer R.M., Wilhelm J.E. Identification of novel filament-forming proteins in Saccharomyces cerevisiae and Drosophila melanogaster. J. Cell Biol. 2010, 190:541-551.
85. Obermayer-Straub P., Manns M.P. Hepatitis C and D, retroviruses and autoimmune manifestations. J. Autoimmun. 2001, 16:275-285.
86. Ochs R.L., Stein T.W., Chan E.K.L., Ruutu M., Tan E.M. cDNA cloning and characterization of a novel nucleolar protein. Mol. Biol. Cell 1996, 7:1015-1024.
87. O'Connell J.D., Zhao A., Ellington A.D., Marcotte E.M. Dynamic reorganization of metabolic enzymes into intracellular bodies. Annu. Rev. Cell Dev. Biol. 2012, 28:89-111.
88. Ohba K., Mizokami M., Lau J.Y., Orito E., Ikeo K., Gojobori T. Evolutionary relationship of hepatitis C, pesti-, flavi-, plantviruses, and newly discovered GB hepatitis agents. FEBS Lett. 1996, 378:232-234.
89. Op De Beeck A., Dubuisson J. Topology of hepatitis C virus envelope glycoproteins. Rev. Med. Virol. 2003, 13:233-241.
90. Pavio N., Lai M.M. The hepatitis C virus persistence: how to evade the immune systemα. J. Biosci. 2003, 28:287-304.
91. Penin F., Dubuisson J., Rey F.A., Moradpour D., Pawlotsky J.M. Structural biology of hepatitis C virus. Hepatology 2004, 39:5-19.
92. Pimkin M., Markham G.D. The CBS subdomain of inosine 5'-monophosphate dehydrogenase regulates purine nucleotide turnover. Mol. Microbiol. 2008, 68:342-359.
93. Probst C., Radzimski C., Blocker I.M., Teegen B., Bogdanos D.P., Stocker W., et al. Development of a recombinant cell-based indirect immunofluorescence assay (RC-IFA) for the determination of autoantibodies against "rings and rods"-associated inosine-5'-monophosphate dehydrogenase 2 in viral hepatitis C. Clin. Chim. Acta 2013, 418:91-96.
94. Radic M.Z., Weigert M. Genetic and structural evidence for antigen selection of anti-DNA antibodies. Annu. Rev. Immunol. 1994, 12:487-520.
95. Ramer M.S., Cruz Cabrera M.A., Alan N., Scott A.L., Inskip J.A. A new organellar complex in rat sympathetic neurons. PLoS One 2010, 5:e10872.
96. Ray K. Hepatitis: NPC1L1 identified as a novel HCV entry factor. Nat. Rev. Gastroenterol. Hepatol. 2012, 9:124.
97. Rosenberg S. Recent advances in the molecular biology of hepatitis C virus. J. Mol. Biol. 2001, 313:451-464.
98. Sainz B., Barretto N., Martin D.N., Hiraga N., Imamura M., Hussain S., et al. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat. Med. 2012, 18:281-285.
99. Satoh M., Chan E.K.L., Sobel E.S., Kimpel D.L., Yamasaki Y., Narain S., et al. Clinical implication of autoantibodies in patients with systemic rheumatic diseases. Expert Rev. Clin. Immunol. 2007, 3:721-738.
100. Satoh M., Vazquez-Del Mercado M., Chan E.K.L. Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases. Mod. Rheumatol. 2009, 19:219-228.
101. Satoh M., Chan E.K.L., Ho L.A., Rose K.M., Parks C.G., Cohn R.D., et al. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum. 2012, 64:2319-2327.
102. Satoh M., Chan J.Y., Ceribelli A., Del-Mercado M.V., Chan E.K.L. Autoantibodies to argonaute 2 (Su antigen). Adv. Exp. Med. Biol. 2013, 768:45-59.
103. Schneiter R., Hitomi M., Ivessa A.S., Fasch E.V., Kohlwein S.D., Tartakoff A.M. A yeast acetyl coenzyme A carboxylase mutant links very-long-chain fatty acid synthesis to the structure and function of the nuclear membrane-pore complex. Mol. Cell. Biol. 1996, 16:7161-7172.
104. Scott J.W., Hawley S.A., Green K.A., Anis M., Stewart G., Scullion G.A., et al. CBS domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations. J. Clin. Invest. 2004, 113:274-284.
105. Seeff L.B. Natural history of hepatitis C. Hepatology 1997, 26:21S-28S.
106. Seelig H.P., Appelhans H., Bauer O., Bluthner M., Hartung K., Schranz P., et al. Autoantibodies against inosine-5'-monophosphate dehydrogenase 2-characteristics and prevalence in patients with HCV-infection. Clin. Lab. 2011, 57:753-765.
107. Simmonds P., Bukh J., Combet C., Deleage G., Enomoto N., Feinstone S., et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005, 42:962-973.
108. Sintchak M.D., Fleming M.A., Futer O., Raybuck S.A., Chambers S.P., Caron P.R., et al. Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Cell 1996, 85:921-930.
109. Smith K.R., Suppiah V., O'Connor K., Berg T., Weltman M., Abate M.L., et al. Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Med. 2011, 3:57.
110. Soo Hoo L., Zhang J.Y., Chan E.K.L. Cloning and characterization of a novel 90kDa 'companion' auto-antigen of p62 overexpressed in cancer. Oncogene 2002, 21:5006-5015.
111. Stinton L.M., Eystathioy T., Selak S., Chan E.K.L., Fritzler M.J. Autoantibodies to protein transport and messenger RNA processing pathways: endosomes, lysosomes, Golgi complex, proteasomes, assemblyosomes, exosomes, and GW bodies. Clin. Immunol. 2004, 110:30-44.
112. Stinton L.M., Myers R.P., Coffin C.S., Fritzler M.J. Clinical associations and potential novel antigenic targets of autoantibodies directed against rods and rings in chronic hepatitis C infection. BMC Gastroenterol. 2013, 13:50.
113. Tan E.M. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv. Immunol. 1989, 44:93-151.
114. Tan E.M. Autoantibodies in pathology and cell biology. Cell 1991, 67:841-842.
115. Tan E.M., Chan E.K.L., Sullivan K.F., Rubin R.L. Antinuclear antibodies (ANAs): diagnostically specific immune markers and clues toward the understanding of systemic autoimmunity. Clin. Immunol. Immunopathol. 1988, 47:121-141.
116. Thomas E.C., Gunter J.H., Webster J.A., Schieber N.L., Oorschot V., Parton R.G., et al. Different characteristics and nucleotide binding properties of inosine monophosphate dehydrogenase (IMPDH) isoforms. PLoS One 2012, 7:e51096.
117. Tillman D.M., Jou N.T., Hill R.J., Marion T.N. Both IgM and IgG anti-DNA antibodies are the products of clonally selective B cell stimulation in (NZB x NZW)F1 mice. J. Exp. Med. 1992, 176:761-779.
118. Vagelos P.R., Alberts A.W., Martin D.B. Activation of acetyl-CoA carboxylase and associated alteration of sedimentation characteristics of the enzyme. Biochem. Biophys. Res. Commun. 1962, 8:4-8.
119. Valentini G., Mantelli A., Persico M., Tuccillo C., Del Vecchio Blanco G., Morisco F., et al. Serological and clinical markers of autoimmune disease in HCV-infected subjects with different disease conditions. Clin. Exp. Rheumatol. 1999, 17:75-79.
120. Verschuur A.C., Van Gennip A.H., Leen R., Meinsma R., Voute P.A., van Kuilenburg A.B. In vitro inhibition of cytidine triphosphate synthetase activity by cyclopentenyl cytosine in paediatric acute lymphocytic leukaemia. Br. J. Haematol. 2000, 110:161-169.
121. Weber G., Prajda N., Abonyi M., Look K.Y., Tricot G. Tiazofurin: molecular and clinical action. Anticancer Res 1996, 16:3313-3322.
122. Willingham M.C., Richert N.D., Rutherford A.V. A novel fibrillar structure in cultured cells detected by a monoclonal antibody. Exp. Cell Res. 1987, 171:284-295.
123. Yao B., Li S., Chan E.K.L. Function of GW182 and GW Bodies in siRNA and miRNA Pathways. Adv. Exp. Med. Biol. 2013, 768:71-96.
124. Zhang J.Y., Zhu W., Imai H., Kiyosawa K., Chan E.K.L., Tan E.M. De-novo humoral immune responses to cancer-associated autoantigens during transition from chronic liver disease to hepatocellular carcinoma. Clin. Exp. Immunol. 2001, 125:3-9.
125. Zhou S., Liu R., Baroudy B.M., Malcolm B.A., Reyes G.R. The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology 2003, 310:333-342.